BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 7776448)

  • 1. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Kinouchi T; Bander NH; Kotake T
    J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal cancer specific antitumor activities of a mouse monoclonal antibody K2.7 to human renal cell carcinoma].
    Kinouchi T; Kotake T
    Hinyokika Kiyo; 1992 Nov; 38(11):1325-31. PubMed ID: 1485589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens.
    Vessella RL; Moon TD; Chiou RK; Nowak JA; Arfman EW; Palme DF; Peterson GA; Lange PH
    Cancer Res; 1985 Dec; 45(12 Pt 1):6131-9. PubMed ID: 3904980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
    Woodhouse CS; Morgan AC
    Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
    Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
    Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas.
    Bander NH; Finstad CL; Cordon-Cardo C; Ramsawak RD; Vaughan ED; Whitmore WF; Oettgen HF; Melamed MR; Old LJ
    Cancer Res; 1989 Dec; 49(23):6774-80. PubMed ID: 2684399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
    Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
    J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
    Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
    Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
    Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
    Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
    Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
    J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
    Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
    Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
    Ishibashi M; Matsuda M; Osafune M; Nakano E; Fujioka H; Takaha M; Sonoda T; Kotake T; Watanabe S
    Hinyokika Kiyo; 1983 Feb; 29(2):121-9. PubMed ID: 6677115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
    Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.